Unicancer
David Aubry is an experienced financial executive with a solid background in financial management and administrative roles. Currently serving as Directeur administratif et financier at UNICANCER since November 2018, David has previously held significant positions including Cadre délégué de gestion DITEP-Pharmacie and Contrôleur de gestion senior at Gustave Roussy from June 2012 to October 2018. Prior to this, David worked as a Contrôleur de gestion senior at Fidelia Assistance from March 2010 to May 2012 and as a Contrôleur de gestion at Gan Assurances from February 2003 to February 2010. David holds a DECF in Comptabilité et finance from ENC Bessières, completed from 2000 to 2002.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries